Skip to content
Medical Health Aged Care

Report on how Australians die reinforces dementia impact on community and healthcare system

Dementia Australia 2 mins read

The What do Australians die from? report released by the Australian Institute of Health and Welfare (AIHW) highlights the most common causes of deaths in Australia. 

The report shows dementia remains the leading cause of death for Australian women and the second leading cause of death of all Australians.

Dementia Australia CEO Professor Tanya Buchanan said dementia is one of the most pressing health challenges facing Australia. 

“With more than 421,000 people living with dementia in Australia, a figure that is expected to double in the next 30 years, dementia has a significant impact in our community and on our health services,” Prof Buchanan said. 

“We know from Australian and international research that dementia is a poorly understood condition, yet it is one of the leading causes of death for Australians. Dementia is not a normal part of the ageing process. It is however, one of the major health challenges facing Australia. 

“Dementia Australia is committed to working towards improving brain health and improving the experience of people living with dementia, their families and carers. For people with a dementia diagnosis, access to appropriate services and care can be fragmented and challenging to access.” 

People impacted by dementia tell us they need:

  • A timely and accurate diagnosis,
  • Access to support services like those provided by Dementia Australia at the time they are diagnosed, including referrals to the National Dementia Helpline, 1800 100 500,
  • Supports services that maintain dignity and autonomy, and
  • Appropriate palliative care services.

“Dementia Australia is committed to working with people impacted by dementia to achieve better outcomes and to reduce the impact of dementia into the future,” Prof Buchanan said.  

“We are proud to be one of the leading funders of research into dementia. 

“There are exciting breakthroughs in research which demonstrate we can start to prevent many cases of dementia as well as being able to offer effective treatment and support services. 

“Dementia Australia through the Dementia Australia Research Foundation is investing in research that will ultimately make a tangible difference to dementia outcomes.”

The Foundation’s research grants are currently open here

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

Media contacts: Gabrielle Prabhu, Media & Communications Manager, 0447 253 583 or Gabrielle.Prabhu@dementia.org.au

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au. 

Media

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.